Healthcare provider profile · identity verified

Robert Carl Brutkiewicz, MD

Family Practice · MOBILE, AL · NPI 1851323000

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	465	137
Omeprazole	Omeprazole	363	112
Metformin Hcl	Metformin Hcl	312	99
Meloxicam	Meloxicam	262	83
Hydrochlorothiazide	Hydrochlorothiazide	250	71
Levothyroxine Sodium	Levothyroxine Sodium	217	64
Tramadol Hcl	Tramadol Hcl	207	55
Amlodipine Besylate	Amlodipine Besylate	198	60
Lisinopril	Lisinopril	172	46
Zolpidem Tartrate	Zolpidem Tartrate	166	28
Clonazepam	Clonazepam	151	23
Metoprolol Succinate	Metoprolol Succinate	143	45
Lorazepam	Lorazepam	133	21
Farxiga	Dapagliflozin Propanediol	132	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	131	37
Trazodone Hcl	Trazodone Hcl	126	28
Furosemide	Furosemide	118	38
Gabapentin	Gabapentin	113	43
Albuterol Sulfate Hfa	Albuterol Sulfate	109	34
Tizanidine Hcl	Tizanidine Hcl	109	23
Ozempic	Semaglutide	106	13
Fluoxetine Hcl	Fluoxetine Hcl	99	29
Glipizide	Glipizide	98	35
Pravastatin Sodium	Pravastatin Sodium	97	27
Fluticasone Propionate	Fluticasone Propionate	93	36
Famotidine	Famotidine	92	26
Citalopram Hbr	Citalopram Hydrobromide	88	28
Losartan Potassium	Losartan Potassium	82	24
Pantoprazole Sodium	Pantoprazole Sodium	82	27
Temazepam	Temazepam	81	21
Rosuvastatin Calcium	Rosuvastatin Calcium	80	30
Tamsulosin Hcl	Tamsulosin Hcl	80	27
Simvastatin	Simvastatin	79	23
Doxycycline Hyclate	Doxycycline Hyclate	76	62
Clonidine Hcl	Clonidine Hcl	67	18
Venlafaxine Hcl Er	Venlafaxine Hcl	67	18
Potassium Chloride	Potassium Chloride	61	17
Allopurinol	Allopurinol	57	18
Prednisone	Prednisone	56	36
Metoprolol Tartrate	Metoprolol Tartrate	49	15
Escitalopram Oxalate	Escitalopram Oxalate	47	12
Oxybutynin Chloride Er	Oxybutynin Chloride	46	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	43	11
Colchicine	Colchicine	42	17
Jardiance	Empagliflozin	42	suppressed
Meclizine Hcl	Meclizine Hcl	42	15
Sertraline Hcl	Sertraline Hcl	42	12
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	41	suppressed
Ibuprofen	Ibuprofen	41	14
Mirtazapine	Mirtazapine	41	18
Fluconazole	Fluconazole	40	23
Naproxen	Naproxen	37	16
Clopidogrel	Clopidogrel Bisulfate	36	12
Paroxetine Hcl	Paroxetine Hcl	36	suppressed
Trulicity	Dulaglutide	36	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	35	27
Bupropion Xl	Bupropion Hcl	34	suppressed
Cefdinir	Cefdinir	33	26
Celecoxib	Celecoxib	33	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	33	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	31	suppressed
Eliquis	Apixaban	29	suppressed
Breo Ellipta	Fluticasone/Vilanterol	27	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	27	13
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	27	suppressed
Clonidine	Clonidine	26	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	suppressed
Januvia	Sitagliptin Phosphate	26	suppressed
Atenolol	Atenolol	25	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	25	11
Pregabalin	Pregabalin	25	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	24	suppressed
Donepezil Hcl	Donepezil Hcl	23	suppressed
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	23	suppressed
Propranolol Hcl	Propranolol Hcl	23	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Ropinirole Hcl	Ropinirole Hcl	23	suppressed
Carvedilol	Carvedilol	22	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	22	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Spironolactone	Spironolactone	21	suppressed
Amoxicillin	Amoxicillin	20	20
Aripiprazole	Aripiprazole	20	suppressed
Alprazolam	Alprazolam	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	13
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	19	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Promethazine Hcl	Promethazine Hcl	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Cephalexin	Cephalexin	17	14
Alendronate Sodium	Alendronate Sodium	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Risperidone	Risperidone	16	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	15	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Lithium Carbonate	Lithium Carbonate	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	11
Ondansetron Hcl	Ondansetron Hcl	14	11
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Sildenafil Citrate	Sildenafil Citrate	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Metformin Hcl Er	Metformin Hcl	11	suppressed
Montelukast Sodium	Montelukast Sodium	11	suppressed
Nystatin	Nystatin	11	suppressed
Ramipril	Ramipril	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error